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Phthalates are used in a variety of industries
and are present in many consumer products,
such as soaps, perfumes, cosmetics, sham-
poos, building products, shower curtains,
aerosols, plastic toys, and plastic packaging
[Agency for Toxic Substances and Disease
Registry (ATSDR) 1995, 2001, 2003]. Di(2-
ethylhexyl) phthalate (DEHP) is the primary
plasticizer in polyvinyl chloride, and diethyl
phthalate (DEP) and dibutyl phthalates
(DBPs) are commonly used in consumer and
personal care products such as lotions, fra-
grances, cosmetics, deodorants, and pharma-
ceutical coatings (ATSDR 1995, 2001,
2003). The reproductive and developmental
toxicities of some phthalates have been
demonstrated extensively in animal studies.
Prenatal exposure to DEHP, DBP, butyl-
benzyl phthalate (BBzP), or, more weakly,
diisononyl phthalate reduces testosterone pro-
duction in fetal testes (Lehmann et al. 2004;
Mylchreest and Foster 2000; Mylchreest et al.
2002; Parks et al. 2000), which can result in
incomplete development of the male repro-
ductive tract and malformations of the exter-
nal genitalia (Ema and Miyawaki 2001; Ema
et al. 2003; Foster et al. 2000; Gray et al.
2000; Mylchreest et al. 1998).
In a study published in a previous issue of
this journal by some authors participating in
the current study, Swan et al. (2005) provided
the first demonstration of subtle developmental
effects, similar to those seen in animal studies,
in human male infants exposed prenatally to
phthalates. The study population for Swan
et al. (2005), described below, included 134
women whose male offspring had a physical
examination by 17 December 2004, of whom
85 had also given a urine sample during preg-
nancy. These prenatal maternal urine samples
were analyzed for nine phthalate metabolites
commonly used as biomarkers of exposure to
phthalates, using an analytical method
described before (Silva et al. 2004b). One hun-
dred thirty-four male infants, including 49 for
whom no maternal prenatal urine sample had
been collected, were physically examined to
determine anogenital distance (AGD)—a
marker for prenatal antiandrogen exposure—
and other reproductive organ measurements.
Of nine urinary phthalate metabolites, Swan
et al. (2005) found that prenatal maternal uri-
nary levels of monoethyl phthalate (MEP; a
metabolite of DEP), monobenzyl phthalate
(MBzP; a metabolite of BBzP), mono-n-butyl
phthalate [MBP; a metabolite of di-n-butyl
phthalate (DnBP)], and monoisobutyl phtha-
late [MiBP; a metabolite of diisobutyl phthalate
(DiBP)] were significantly associated with
reduced AGD and anogenital index (AGI =
AGD/body weight) in male infants.
Although none of the 134 boys examined
showed frank malformations or disease, and
86.6% of these boys had both testicles classified
as normal, AGI was significantly correlated
with degree of testicular descent as well as
penile volume and scrotal size (Swan et al.
2005). The median concentrations of phthalate
metabolites (Table 1) in the Swan et al. study
associated with short AGI and incomplete tes-
ticular descent were similar to the median con-
centrations found in the female population of
the United States, based on the 2001–2002
National Health and Nutrition Examination
Survey (NHANES) (National Center for
Environmental Health 2005).
The current U.S. Environmental Protection
Agency (EPA) reference doses (RfDs) for DEP,
DBP, and BBzP were formulated in the early
1990s using older animal studies (DBP was
completed in 1990; DEP and BBzP in 1993)
(U.S. EPA 2005a, 2005c, 2005d). The RfD, as
defined by the U.S. EPA, is intended to be a
dose for which daily oral exposure to the human
population (including sensitive subgroups) is
likely to be without an appreciable risk of dele-
terious effects during a lifetime. Because the
data presented by Swan et al. (2005) suggested
subtle human developmental effects at levels of
exposure similar to those observed in the gen-
eral population, that study may provide
important information when considering any
future updates to RfDs for phthalates. For that
study to be useful for this purpose, it is neces-
sary to estimate the average daily exposures of
phthalates for the study individuals.
In this study, we applied a simple phar-
macokinetic model, initially proposed by
Kohn et al. (2000) and later used by Koo
et al. (2002), to estimate the individual daily
exposure of phthalate diesters in the pregnant
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Phthalate diesters have been shown to be developmental and reproductive toxicants in animal
studies. A recent epidemiologic study showed certain phthalates to be significantly associated with
reduced anogenital distance in human male infants, the first evidence of subtle developmental
effects in human male infants exposed prenatally to phthalates. We used two previously published
methods to estimate the daily phthalate exposures for the four phthalates whose urinary metabo-
lites were statistically significantly associated with developmental effects in the 214 mother–infant
pairs [di-n-butyl phthalate (DnBP), diethyl phthalate (DEP), butylbenzyl phthalate (BBzP),
diisobutyl phthalate (DiBP)] and for another important phthalate [di-2-ethylhexyl phthalate
(DEHP)]. We estimated the median and 95th percentile of daily exposures to DBP to be 0.99 and
2.68 µg/kg/day, respectively; for DEP, 6.64 and 112.3 µg/kg/day; for BBzP, 0.50 and 2.47
µg/kg/day; and for DEHP, 1.32 and 9.32 µg/kg/day. The U.S. Environmental Protection Agency
(EPA) reference doses for these chemicals are 100 (DBP), 800 (DEP), 200 (BBzP), and 20
(DEHP) µg/kg/day. The median and 95th percentile exposure estimates for the phthalates associ-
ated with reduced anogenital distance in the study population are substantially lower than current
U.S. EPA reference doses for these chemicals and could be informative to any updates of the haz-
ard assessments and risk assessments for these chemicals. Key words: anogenital distance, butyl-
benzyl phthalate, di(2-ethylhexyl) phthalate, dibutyl phthalate, diethyl phthalate, diisobutyl
phthalate, exposure estimates, reference dose. Environ Health Perspect 114:805–809 (2006).
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women in the Swan et al. (2005) study popu-
lation. We also used a second model, initially
proposed by David (2000), to provide com-
parisons for our exposure estimates generated
by the first model.
Materials and Methods
Study population. Women included in this
study were originally recruited into the Study
for Future Families (SFFI), a multicenter
pregnancy cohort study, at prenatal clinics in
Los Angeles, California (Harbor-UCLA and
Cedars-Sinai); Minneapolis, Minnesota
(University of Minnesota Health Center); and
Columbia, Missouri (University Physicians),
from September 1999 through August 2002.
Details of study participation are given by
Swan et al. (2005). All participants completed
a questionnaire, and after urine collection was
added midway through the study, most gave a
urine sample. Eighty-five percent of SFFI par-
ticipants agreed to be recontacted, and these
mothers were invited to take part in the SFF
follow-up study (SFFII) (Swan et al. 2005).
Human subject committees at all participat-
ing institutions approved the SFFI and SFFII,
and all participants signed an informed con-
sent for each study.
In the Swan et al. (2005) study, the authors
reported on results in boys for whom a first pre-
natal visit had been completed by 17 December
2004. These included 172 boys, 134 of whom
had complete data for AGD, age, and weight.
Urinary phthalate metabolite concentrations in
214 mother–infant pairs were also obtained
(girls and boys), of whom 85 were boys with
measurements of AGD and complete data on
age and weight and whose mother had given a
prenatal urine sample. We used the urinary
phthalate monoester concentrations from the
study population of 214 mother–infant pairs to
calculate daily exposure estimates. The
monoester concentrations for the complete
study population (n = 214) are shown in Table
1. This study population has urinary monoester
concentrations very similar to those found in
the subset of this population (n = 85) used by
Swan et al. (2005). Distributions of phthalate
metabolites among the groups of 85 and
214 women are similar. The median mono-
ester concentrations in the group of 85 were
128.4 ng/mL (MEP), 13.5 ng/mL (MBP),
8.3 ng/mL (MBzP), 2.5 ng/mL (MiBP),
3.3 ng/mL (MEHP), 11.4 ng/mL (MEHHP),
and 11.1 ng/mL (MEOHP). We evaluated the
larger sample because it provides more informa-
tion on the distribution of phthalate exposures.
We calculated daily exposure for the
phthalate metabolites that were statistically sig-
nificantly associated with reduced AGI in the
Swan et al. (2005) study, and the metabolites
of DEHP. Although metabolites of DEHP
were not significantly associated with AGI in
the Swan et al. study, the associations for two
oxidative metabolites of DEHP [mono(2-
ethyl-5-oxohexyl) phthalate (MEOHP) and
mono(2-ethyl-5-hydroxyhexyl) phthalate
(MEHHP)] were of magnitudes comparable
with those for metabolites of DBP and BBzP.
Moreover, there is an extensive animal litera-
ture showing DEHP-mediated androgen-
related effects.
Daily exposure estimates. Kohn et al.
(2000) calculated the daily exposure for each
individual in the population by using a linear
two-compartment model. The normalized
integrated rate equations for fractional excre-
tion are as follows:
FE = 1 – exp (–ktotalt ) [1]
FU = 
ku
ktotal
[1 – exp (–ktotalt )], [2]
where FE is the total fraction and FU is the
urinary fraction of the dose eliminated in time
t, and ktotal and ku are the apparent first-order
rate constants for total elimination and urinary
elimination of monoester, respectively. We
calculated the two rate constants, ktotal and ku,
by using previously published values for the
excreted fractions of each parent diester (Kohn
et al. 2000; Koo et al. 2002). Values of FE and
FU from Kohn et al. (2000), originally calcu-
lated from animal and human studies, were
used for all metabolites reported by Swan et al.
(2005), except for MiBP, which was not con-
sidered by Kohn et al. We assumed that the
FE and FU for MiBP and its parent diester
were equal to those calculated for MBP and
DnBP. The excretion rate equations are used
to estimate ktotal and ku for input into the
equation from Kohn et al. (2000) that esti-
mates phthalate exposure.
Kohn et al. (2000) provide the following
equation for the exposure rate for an individ-
ual, assuming steady-state exposure and meta-
bolic clearance of the diester:
Daily intake (μg/kg/day) =
[3]
where ME is the urinary concentration of
monoester per gram of creatinine, CE is the
creatinine excretion rate normalized by body
weight, f is the ratio of urinary excretion to
total elimination (ku/ktotal), and MWd and
MWm are the molecular weights of the
diesters and monoesters, respectively. We
used a value of 18 mg/kg/day for CE (Kohn
et al. 2000) and creatinine-adjusted concen-
trations (ME) for each subject in the study.
The unadjusted and creatinine adjusted
phthalate urinary concentrations from the
214 samples from the Swan et al. (2005)
study are shown in Table 1.
For comparison, we also estimated the
daily exposure using a second formula pub-
lished by David (2000), and later used by
Koch et al. (2003):
Daily intake (μg/kg/day) = 
[4]
This formula is an alternate version of the
method of Kohn et al. (2000) and results in
similar exposure values (Koch et al. 2003).
ME CE
F
MW
MUE
d(μg/g) (mg/kg/day)
(mg/g)
×
×
×
1 000, Wm
(μg/g) (mg/kME CE× g/day)
(mg/g)f
MW
MW
d
m×
×
1 000,
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Table 1. Urinary phthalate monoester concentrations (ng/mL urine, µg/g creatinine) from a study popula-
tion of 214 pregnant women from Swan et al. (2005).a
Phthalate 25th percentile Median 75th percentile 95th percentile Maximum NHANES medianb
MEP
ng/mL 50 117 466 3,199 30,528 167
µg/g creatinine 71.1 108 506 3,015 33,932 171
MBzP
ng/mL 3.6 9.3 20.9 57.8 436 15.4
µg/g creatinine 6.5 11.7 21.6 58 364 15.1
MBP
ng/mL 7.4 16.2 29.6 64.5 337 21.6
µg/g creatinine 13.8 20.6 32.2 57.3 144 21.5
MiBP
ng/mL < LOD 2.5 4.7 13.1 39.8 2.50
µg/g creatinine < LOD 2.9 5.1 10.0 71.1 2.83
MEHP
ng/mL 1.5 4.25 11.0 38.6 206.8 4.10
µg/g creatinine 2.15 5.53 14.0 39.2 172.8 4.43
MEHHP
ng/mL 5.6 10.8 21.7 76.4 2,108 18.2
µg/g creatinine 8.4 13.0 26.9 88.9 1,254 17.6
MEOHP
ng/mL 5.1 9.75 21.0 65.0 1,677 13.0
µg/g creatinine 7.7 12.6 23.1 80.5 998 12.0
LOD, limit of detection. 
aSwan et al. (2005) report phthalate concentrations for the 85 infant–mother pairs with sufficient data for the epidemio-
logic analysis. The present analysis uses the original sample of 214 with urinary metabolite concentrations (see
“Materials and Methods”). bThe median concentration in the general female (older than 6 years) population from
NHANES 2001–2002 (National Center for Environmental Health 2005).
The variables used are the same as those used
in the Kohn et al. formula, except FUE, the
molar fraction of the urinary excreted
monoester related to the parent diester, is
used in place of f. The fractional urinary
excretion values for DBP (0.69) and BBzP
(0.73) were taken from published human data
(Anderson et al. 2001). For DEP, we pre-
sumed the excretion factor to be the same as
that for DBP, as done by Koch et al. (2003)
and Kohn et al. (2000). The fractional excre-
tion data for the three DEHP metabolites
measured in the Swan et al. (2005) study
were taken from recently published human
data (Koch et al. 2005). The values for
mono(2-ethylhexyl) phthalate (MEHP),
MEHHP, and MEOHP are 0.059, 0.233,
and 0.150, respectively.
We calculated DEHP exposures based on
each of the three metabolites independently,
and also based on the averages of the expo-
sures calculated using the secondary metabo-
lites (MEHHP and MEOHP). DEHP is
initially metabolized to MEHP, which is then
further metabolized to various other products,
including MEHHP and MEOHP. All three
metabolites are thought to be toxic (Koch
et al. 2005), and estimating DEHP exposure
based on the three different metabolites allows
for comparison of the various estimates. We
treated the concentrations of MBP and MiBP
as one combined measure of exposure to DBP.
This makes it consistent with previous litera-
ture on DBP, which did not distinguish
between iso- and n-butyl isomers. We consid-
ered MBzP to be the main metabolite of
BBzP. MBP is a minor metabolite of BBzP,
but only 6% of the ingested BBzP diester is
excreted as MBP (Anderson et al. 2001).
Results
The results for the exposures of DEP, DBP,
and BBzP of the women in the Swan et al.
(2005) study, as calculated using the Kohn
et al. (2000) method, are presented in
Table 2. The relevant monoesters are pre-
sented with their parent diesters. Using the
Kohn et al. formula, we estimated the median
and 95th percentile of daily exposures for
DBP to be 0.99 and 2.68 μg/kg/day, respec-
tively; DEP, 6.64 and 112.3 μg/kg/day;
BBzP, 0.50 and 2.47 μg/kg/day; and DEHP,
1.32 and 9.32 μg/kg/day.
The estimated exposures calculated using
the David (2000) formula are compared with
the Kohn et al. (2000) method estimates in
Table 3. The David method produces expo-
sure estimates that are typically about 20%
lower. The exception is DEHP, which is
about 30–80% higher based on the David
method, depending on which metabolites are
used for the calculation.
Discussion
We have estimated exposures to a variety of
phthalate diesters in a population of
mother–infant pairs in which subtle develop-
mental effects were associated with prenatal
urinary phthalate metabolite concentrations.
The models we have used to estimate expo-
sures make no assumptions regarding the route
of exposure. There are multiple possible routes
of exposure to phthalates, including dermal
(Duty et al. 2005), ingestion (Clark et al.
2003), and inhalation (Adibi et al. 2003).
Furthermore, phthalate diesters and their
metabolites are cleared from the body within a
few days, with the bulk of the dose cleared
within the first 24 hr (Anderson et al. 2001;
Koch et al. 2005). There were relatively few
nondetects in the population, indicating that
exposures of the levels observed in this study
reflect relatively continuous daily exposures.
The median estimated exposures for DBP
and BBzP in the Swan et al. (2005) study
population (n = 214) are on the order of 1
μg/kg/day, and for DEP are on the order of 6
μg/kg/day. Current U.S. EPA RfDs are 100
μg/kg/day (DBP), 200 μg/kg/day (BBzP), and
800 μg/kg/day (DEP), which are all more
than 100 times greater than the median expo-
sures in the Swan et al. (2005) population.
There are potential sources of uncertainty
in the Kohn et al. (2000) and David (2000)
formulas. Creatinine excretion rates are
known with 10% accuracy (Kohn et al.
2000). Furthermore, Kohn et al. discuss the
potential uncertainty within the total and uri-
nary excretion values (FE and FU). Because
Kohn et al. used animal excretion data for
some of the metabolites, they estimated that
their FE values were accurate to approxi-
mately 50%, whereas the FU values could
vary by 15-fold among species with humans
in the middle. However, we used fractional
urinary excretion values obtained from
human studies in our calculations using the
David formula. There has been much scien-
tific debate regarding the appropriate use of
FUE values when using the David formula to
calculate DEHP exposure values. David
(2004) has argued in favor of using an FUE for
MEHP of 13%, calculated from human
excretion data provided by Anderson et al.
(2001). In a reply to David (2004), Koch
et al. (2004) support their use of an FUE for
MEHP of 2.4% and also provide a mathe-
matical argument against the feasibility of
13% as the FUE for MEHP. The choice of
FUE values is important because it affects the
results of the exposure calculations. We use
FUE values from the most recent human
excretion data on DEHP (Koch et al. 2005).
Our MEHP FUE of 5.9% falls in between the
values previously proposed by David and
Koch et al. Our exposure calculations using
this value are in close agreement with our cal-
culations using the oxidative metabolites of
DEHP (MEHHP and MEOHP), and with
our calculations using the Kohn et al.
method, which does not use FUE values. Our
exposure estimates from the Kohn et al. and
Maternal daily phthalate exposures
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Table 2. Estimated phthalate exposure (µg/kg/day), calculated using the Kohn et al. (2000) method, for 214
pregnant women from Swan et al. (2005). 
Monoester Diester (parent) 25th percentile Median 75th percentile 95th percentile Maximum
MEP DEP 2.65 6.64 18.82 112.3 1,263
MBzP BBzP 0.28 0.50 0.092 2.47 15.53
MBP DnBP 0.56 0.84 1.31 2.33 5.86
MiBP DiBP NAa 0.12 0.21 0.41 2.90
MiBP + MBP DnBP + DiBP 0.63 0.99 1.53 2.68 5.98
MEHP DEHP 0.51 1.32 3.32 9.32 41.10
NA, not applicable. The phthalates shown are those that were significantly associated with reduced AGD and AGI (Swan
et al. 2005), along with MEHP. Current U.S. EPA RfDs are 100 (DBP), 200 (BBzP), (DEP), and 20 (DEHP) µg/kg/day (U.S. EPA
2005a, 2005b, 2005c, 2005d). 
aThe daily exposure was not estimated when the urinary concentration of the phthalate metabolite was < limit of detection.
Table 3. Estimated daily exposure values of phthalates to the pregnant women of Swan et al. (2005) study
population based on the Kohn et al. (2000) and the Davida (2000) methods.b
Kohn et al. method David method
Metabolite Diester Median 95th percentile Range Median 95th percentile Range
MEPc DEP 6.64 112.3 0–1,263 5.32 90.0 < LOD to 1,013
MBzPc BBzP 0.50 2.47 0–15.5 0.35 1.74 < LOD to 10.9
MBPc DnBP 0.84 2.34 0–5.86 0.67 1.87 < LOD to 4.70
MiBPc DiBP 0.12 0.41 0–2.90 0.09 0.33 < LOD to 2.3
MBP + MiBP DBP 0.99 2.68 0–5.98 0.79 2.15 < LOD to 2.15
MEHHP DEHP 1.33 9.11 < LOD to 128.5
MEOHP DEHP 2.00 12.8 < LOD to 158.9
Averaged DEHP 1.70 10.72 < LOD to 143.7
MEHP DEHP 1.32 9.32 0–41.1 2.37 16.8 < LOD to 73.9
LOD, limit of detection. 
aFUE values for MEHP, MEHHP, and MEOHP are 0.059, 0.233, and 0.150, respectively, based on human data from Koch
et al. (2005). bCurrent U.S. EPA RfDs are 20 (DEHP), 100 (DBP), 200 (BBzP), and 800 (DEP) µg/kg/day (U.S. EPA 2005a, 2005b,
2005c, 2005d). cStatistically significantly associated with reduced AGI in the Swan et al. (2005) study. dAverage of the
exposure estimates using MEHHP and MEOHP.
David formulas are similar, suggesting reason-
able agreement between the models and
parameters used.
The exposures within this study population
of pregnant women are similar to or some-
what lower than those documented in other
populations of women of reproductive age.
Median female (all ages above 6 years) MBP
concentrations in NHANES 2001–2002
(21.5 μg/g creatinine) compare closely with
those in the Swan et al. (2005) study popula-
tion (20.6 μg/g creatinine), and median
2001–2002 NHANES MBzP concentrations
(15.1 μg/g creatinine) were similar to those in
the Swan et al. study population (11.7 μg/g cre-
atinine) (National Center for Environmental
Health 2005). In the population of 97
women 20–40 years of age that was evaluated
in the Kohn et al. (2000) study, the median
concentrations of MBP, MBzP, MEP, and
MEHP were greater than those in the Swan
et al. study population. A population of
25 pregnant women in New York City exhib-
ited median MBP, MEP, and MBzP urinary
concentrations within the same order of mag-
nitude but higher than those observed in the
Swan et al. study population (Adibi et al.
2003). 
Except for the Adibi et al. (2003) study,
the studies mentioned above deal primarily
with women who are not pregnant, whereas
the women in the Swan et al. (2005) study
population were pregnant. Differences in
fluid level and metabolism between pregnant
and nonpregnant states may account for some
of these differences. Alternatively, the differ-
ences among the study populations may rep-
resent temporal differences in exposures to
phthalate-containing materials. The Kohn
et al. (2000) study evaluated samples collected
from 1988–1994 (NHANES III), whereas
the Adibi et al. (2003) study evaluated sam-
ples collected in 2000. Samples from the
Swan et al. (2005) study population were col-
lected from 2000 through 2003.
As discussed in the Swan et al. (2005)
study, the observed relationships between pre-
natal phthalates and AGD in male infants are
similar to those observed in animal studies, in
which those changes are seen only at higher
doses (Swan et al. 2005). For DBP,
Mylchreest et al. (2000) found androgen-
dependent effects from exposure in rats, such
as decreased AGD, retained areolas or nipples,
and reproductive tract malformations. The
most sensitive end point observed was a dose-
dependent increase in the incidence of tho-
racic areola and nipple development. When
compared with the control animals, the lowest
statistically significant dose group was at 100
mg/kg/day (100,000 μg/kg/day). This is well
above the values obtained from the Swan et al.
study. Some of the difference could be attrib-
uted to the difference in study design, in
which Mylchreest et al. compared each dose
group only with the controls and did not pre-
sent an overall test for trend among the doses,
in contrast to the Swan et al. study, which
looked at a continuous dose response func-
tion. It may also suggest that humans could be
more sensitive than animals to exposures to
phthalates. A separate study (Lehmann et al.
2004) demonstrated statistically significantly
reduced fetal testicular testosterone production
with daily DnBP administration as low as 50
mg/kg/day in experimental rats. Alterations to
the activity of enzymes involved in the pro-
duction of testosterone were observed at DnBP
levels as low as 0.1 mg/kg/day. Given the small
sample size of the study (four to five fetuses per
treatment group), it is possible that effects at
DnBP doses < 50 mg/kg/day might signifi-
cantly reduce fetal testosterone production in
animal models.
In addition, the observed associations in
the Swan et al. (2005) study at the lower con-
centrations could reflect the “real-world” sce-
nario that occurs in the human population,
where exposure to any individual chemical of
interest occurs simultaneously with exposures
to other environmental factors that could
affect the dose at which effects are seen. In the
Swan et al. study, multiple phthalates, many
of which have androgen-related effects (Gray
et al. 2000; Lehmann et al. 2004; Mylchreest
et al. 2000; Parks et al. 2000), were detected
in the women. In the animal studies, only one
chemical is assessed at a time, which cannot
account for the effect of multiple exposures
that occur in the human population. Recent
research with rats dosed with mixtures of
chemical antiandrogens, including DBP,
DEHP, BBzP, and four different herbicides,
indicates that all tested mixtures of these
chemicals acted to produce cumulative,
apparently dose-additive effects on androgen-
dependent tissues (Gray et al. 2006).
Swan et al. (2005) found subtle develop-
mental effects associated with phthalate expo-
sures in a human population. The exposures
that are associated with these subtle develop-
mental reproductive effects in male infants are
comparable with exposures observed in other
female populations in the United States
(Adibi et al. 2003; Blount et al. 2000;
National Center for Environmental Health
2005; Silva et al. 2004a) and are two orders of
magnitude lower than the reference doses
assumed to be protective by the U.S. EPA
(U.S. EPA 2005a, 2005b, 2005c, 2005d).
The values of our exposure estimates are in
close agreement when calculated using two
different models and different excretion fac-
tors. We have provided exposure estimates for
the phthalates deemed to have had health
effects in this study population. This informa-
tion is an asset to any future updates of the
RfDs for these phthalates.
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